Advertisement
Advertisement

HIV Care Today


Not by Ourselves: The Essential Role of Family and Community in Maintaining Health
By David Fawcett, Ph.D., L.C.S.W.
February 12, 2013

In the modern world it can be remarkably easy to discover where you are. A simple tap on the screen of a smart phone or consultation with a car's GPS device instantly reports our location on the planet with almost absurd precision. Such effortless ability to locate ourselves in time and space can shroud the complications of maintaining emotional bearings in the more ambiguous, upside-down world of living with HIV. Those who are newly diagnosed, as well as long-term survivors, are buffeted by the powerful forces unleashed by living with or around HIV, and frequently find it challenging to maneuver this emotional realm.

Read more …


Innovative HIV Gene Therapy Study Soon to Start Enrollment
By Nelson Vergel, B.S.Ch.E., M.B.A.
January 17, 2013

Calimmune, a small biotechnology company, has been given the go-ahead by the U.S. Food and Drug Administration to start enrolling HIV-infected people in a first-of-its-kind gene therapy study that will modify two HIV attachment sites in CD4+ cells.

Read more …


More Evidence That Early HIV Treatment -- REALLY Early -- Is Beneficial
By Paul E. Sax, M.D.
January 16, 2013

Management of recently acquired HIV infection -- especially acute HIV, pre-seroconversion -- has long been controversial, with the risks and benefits of treatment versus observation debated now for nearly two decades.

(Yes, it's been that long since the publication of this controlled trial of zidovudine monotherapy. Amazing.)

Read more …


How Can "JAK Inhibitors" Help Salvage Patients and the Search for an HIV Cure?
By Nelson Vergel, B.S.Ch.E., M.B.A.
January 15, 2013

As part of my work as an HIV cure and salvage treatment activist, I am constantly searching for treatment options that could serve two purposes: help patients with multidrug resistance, and at the same time be used as an approach to cure HIV. Since my nonprofit, Program for Wellness Restoration (PoWeR), has a very small budget for me to attend conferences, I rely on the summaries that Jules Levin and his group at National AIDS Treatment Advocacy Project (NATAP) publish after he attends conferences. I am glad Jules can serve as eyes and ears for those of us who are unable to attend so many important scientific meetings.

Read more …


HIV Exceptionalism Is Alive and Well -- and That's Too Bad
By Paul E. Sax, M.D.
January 9, 2013

Email exchange with a colleague who works at one of our community health clinics:

Guy: Hi Paul, your patient 17432862 [that's a made-up medical record number] came to our walk-in clinic with a rash on her hand. OK that I gave her a week of topical steroids? I know how inhaled steroids interact with some meds -- wasn't sure about the creams.

Me: Could be, good thought. Regardless, a short course should be fine. Tell me, who is the patient? What meds is she on?

Guy: I didn't want to put her name or meds in the email, what with her disease state, HIPAA, etc.

Read more …


What's a Fulyzaq? I Thought You'd Never Ask
By Paul E. Sax, M.D.
January 3, 2013

As Physician's First Watch noted, we sure know what the folks at the FDA were doing this holiday season -- and most emphatically they weren't visiting Aunt Selma in Boca Raton.

Read more …


HIV Incidence: The Latest Numbers
By Paul E. Sax, M.D.
January 1, 2013

The CDC has recently issued the latest report on HIV incidence (i.e., new infections) in the United States, and as always it's fascinating to review the numbers.

Read more …


The U.S. Preventive Services Task Force Recommends HIV Screening -- And Why Is This News?
By Paul E. Sax, M.D.
November 22, 2012

A flurry of coverage recently appeared about the U.S. Preventive Services Task Force's recommendation for one-time HIV screening for all Americans, ages 15-64.

Some might wonder why this is news -- um, hasn't this been recommended now for years? -- and I think I've figured it out.

Read more …


The 800-mg Darunavir Tablet Arrives, and Scoring the Top Protease Inhibitors
By Paul E. Sax, M.D.
November 18, 2012

The FDA has approved an 800-mg tablet of darunavir for treatment naive patients. This single tablet will obviously replace the two darunavir 400-mg tablets in first-line therapy. (Yes, my math is that good.) Darunavir will still require 100-mg ritonavir boosting plus two NRTIs to make a complete regimen.

Read more …


Vitamins and the Department of Bad Timing
By Paul E. Sax, M.D.
November 7, 2012

Now that the election is over, we can get back to something that really matters -- namely vitamins, and specifically whether they really help people.

Read more …

 < Prev  |  1  |  …  |  3  |  4  |  5  |  6  |  7  |  …  |  14  |  Next > 

Get email notifications every time HIV Care Today is updated.



This article was provided by TheBodyPRO.com.
 

Advertisement